Page 113 - Read Online
P. 113

Page 4 of 4                  Sinagra et al. Vessel Plus 2022;6:44  https://dx.doi.org/10.20517/2574-1209.2021.143

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2022.


               REFERENCES
               1.       Porcari A, Pagura L, Rossi M, et al. Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to
                   cyclophosphamide, bortezomib, and dexamethasone combined therapy. Eur Heart J Case Rep 2022;6:ytac130.  DOI  PubMed  PMC
               2.       Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J
                   Intern Med 2020;82:7-15.  DOI  PubMed  PMC
               3.       Porcari A, Bussani R, Merlo M, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly
                   patients undergoing post-mortem examination. Front Cardiovasc Med 2021;8:749523.  DOI  PubMed  PMC
               4.       De Gaspari M, Finato N, Basso C, et al. Cardiac amyloidosis: the pathologist’s point of view. Vessel Plus 2022;5:[Accept].
               5.       Aimo A, Merlo M, Porcari A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of
                   screening studies. Eur J Heart Fail 2022;Online ahead of print.  DOI  PubMed
               6.       Canepa M, Vianello PF, Porcari A, Merlo M, Scarpa M. Cardiac amyloidosis: a changing epidemiology with open challenges. Vessel
                   Plus 2022;6:30.  DOI
               7.       Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of
                   the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail 2022;Online ahead of print.  DOI  PubMed
               8.       Porcari A, Pagura L, Longo F, et al. Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal
                   tunnel surgery. ESC Heart Fail 2022;9:751-60.  DOI  PubMed  PMC
               9.       Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
                   DOI  PubMed
               10.      Porcari A, Rossi M, Dore F, et al. Ten questions for the cardiologist about cardiac scintigraphy with bone tracers, amyloidosis and the
                   heart. G Ital Cardiol (Rome) 2022;23:424-32.  DOI  PubMed
               11.      Mattana F, Muraglia L, Girardi F, et al. Clinical application of cardiac scintigraphy with bone tracers: controversies and pitfalls in
                   cardiac amyloidosis. Vessel Plus 2022;6:13.  DOI
               12.      Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven factors predict a delayed diagnosis of cardiac
                   amyloidosis. Amyloid 2018;25:174-9.  DOI  PubMed
               13.      Pica S, Lombardi M. Disclosing the cardiomyopathic substrate within the heart muscles in amyloidosis by cardiac magnetic resonance:
                   diagnostic and prognostic implications. Vessel Plus 2022;6:10.  DOI
               14.      Genovesi D, Giorgetti A. Nuclear medicine techniques for the diagnosis of cardiac amyloidosis: the state of the art. Vessel Plus
                   2021;5:50.  DOI
               15.      Porcari A, Rossi M, Cappelli F, et al. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac
                   amyloidosis. Eur J Heart Fail 2022;24:1227-36.  DOI  PubMed
               16.      Porcari A, Pagura L, Varrà GG, et al. Grey zones in the supportive treatments of cardiac amyloidosis. Vessel Plus 2022;6:33.  DOI
               17.      Scirpa R, Russo D, Tini G, et al. Clinical translation of genetic testing in TTR amyloidosis: genotype-phenotype correlations,
                   management of asymptomatic carriers and familial screening. Vessel Plus 2022;6:[Accept].
               18.      Camerini L, Aimo A, Pucci A, et al. Serum and tissue light-chains as disease biomarkers and targets for treatment in AL amyloidosis.
                   Vessel Plus 2022;6:[Accept].
               19.      Licordari R, Minutoli F, Cappelli F, et al. Mid-basal left ventricular longitudinal dysfunction as a prognostic marker in mutated
                   transthyretin-related cardiac amyloidosis. Vessel Plus 2022;6:12.  DOI
               20.      Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis.
                   JACC Basic Transl Sci 2019;4:438-48.  DOI  PubMed  PMC
               21.      Di Nora C, Sponga S, Nalli C, et al. Heart transplantation in cardiac amyloidosis. Vessel Plus 2022;6:[Accept].
               22.      Di Nora C, Sponga S, Ferrara V, et al. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian
                   single-centre experience in heart transplantation. J Cardiovasc Med (Hagerstown) 2021;22:261-7.  DOI  PubMed
   108   109   110   111   112   113   114   115   116   117   118